Study identification

EU PAS number

EUPAS1000000332

Study ID

1000000332

Official title and acronym

A global evaluation of the economic impact of time to initiation of biologic treatment of severe asthma patients

DARWIN EU® study

No

Study countries

Argentina
Australia
Belgium
Bulgaria
Canada
Colombia
Denmark
Estonia
Greece
India
Ireland
Italy
Korea, Republic of
Kuwait
Mexico
Norway
Poland
Portugal
Saudi Arabia
Singapore
Spain
Sweden
Taiwan
United Arab Emirates
United Kingdom
United States

Study description

This study aims to identify the effect of time to initiation of biologic treatment of severe asthma patients on lifetime cost and disease burden at both global and national levels. The study will proceed through a systematic two-step process: (i) identification of biologic initiation and its clinical implications using the ISAR database and (ii) development of economic models to understand the cost-effectiveness of early versus late or non-initiation.

1. Calculation of national-level estimates:
• Utilise retrospective ISAR and other published data to derive national-level estimates for model parameters and inputs.
2. Development of cumulative national disease burden:
• Utilize a validated economic model22 to generate and estimate scenarios comparing earlier biologic initiation versus later initiation.
3. Cross-country comparison
• Explore factors contributing to observed variation between countries, including differences in healthcare infrastructure, treatment accessibility, or patient demographics.

Study status

Finalised
Research institutions and networks

Institutions

Respiratory Effectiveness Group

Contact details

Brett McQueen

Primary lead investigator

Study timelines

Date when funding contract was signed

Planned:
Actual:

Study start date

Planned:
Actual:

Data analysis start date

Planned:
Actual:

Date of interim report, if expected

Planned:
Actual:

Date of final study report

Planned:
Actual:
Sources of funding
Pharmaceutical company and other private sector 

More details on funding

AstraZeneca
Regulatory

Was the study required by a regulatory body?

No

Is the study required by a Risk Management Plan (RMP)?

Not applicable